1.1. Давыдов М.И., Аксель Е.М. Статистика злокачественных новообразований в России и странах СНГ в 2009 г. Вестник РОНЦ им. Н.Н.Блохина. 2011; 22 (3).2.2. Чиссов В.И., Старинский В.В., Петрова Г.В. Злокачественные новообразования в России в 2009 г. (заболеваемость и смертность). М.: ФГУ МНИОИ им. П.А.Герцена Минздравсоцразвития РФ. 2011.3.3. Bray F, Loos AH, Tognazzo S et al. Ovarian cancer in Europe: cross-sectional trends in incidence and mortality in 28 countries, 1953-2000. Int J Cancer 2005; 113: 977-90.4.4. Брюс Э. Чебнэр, Томас Дж. Линч, Дэн Л. Лонго. Руководство по онкологии. Пер. с англ. Под ред. В.А.Хайленко. М.: МЕДпресс-информ, 2011.5.5. Tinelli A, Vergara D, Martignago R et al. An outlook on ovarian cancer and borderline ovarian tumors: focus on genomic and proteomic findings. Curr Genomics 2009; 10 (4): 240-9.6.6. Бохман Я.В. Руководство по онкогинекологии. СПб.: Фолиант, 2002.7.7. Boyd J. Molecular genetics of hereditary ovarian cancer. Oncology (Williston Park) 1998; 12 (3): 399-406.8.8. La Vecchia C. Epidemiology of ovarian cancer: a summary review. Eur J Cancer Prev 2001; 10 (2): 125-9.9.9. Negri E, Pelucchi C, Franceschi S et al. Family history of cancer and risk of ovarian cancer. Eur J Cancer 2003; 39 (4): 505-10.10.10. Deng CX. BRCA1: cell cycle checkpoint, genetic instability, DNA damage response and cancer evolution. Nucleic Acids Res 2006; 34 (5): 1416-25.11.11. Sankaran S, Starita LM, Simons AM et al. Identification of domains of BRCA1 critical for the ubiquitin-dependent inhibition of centrosome function. Cancer Res 2006; 66 (8): 4100-7.12.12. Tutt A, Ashworth A. The relationship between the roles of BRCA genes in DNA repair and cancer predisposition. Trends Mol Med 2002; 8 (12): 571-6.13.13. Yoshida K, Miki Y. Role of BRCA1 and BRCA2 as regulators of DNA repair, transcription, and cell cycle in response to DNA damage. Cancer Sci 2004; 95 (11): 866-71.14.14. Prat J, Ribe A, Gallardo A. Hereditary ovarian cancer. Hum Pathol 2005; 36 (8): 861-70.15.15. Jasin M. Homologous repair of DNA damage and tumor genesis: the BRCA connection. Oncogene 2002; 21 (58): 8981-93.16.16. Dang CV, Resar LM, Emison E et al. Functions of the c-Myc oncogenic transcriptions factor. Exp Cell Res 1999; 253 (1): 63-77.17.17. Lavin MF, Gueven N. The complexity of p53 stabilization and activation. Cell Death Differ 2006; 13 (6): 941-50.18.18. O\'Driscoll M, Jeggo PA. The role of double-strand break repair - insights from human genetics. Nat Rev Genet 2006; 7 (1): 45-54.19.19. Simon MS, Petrucelli N. Hereditary breast and ovarian cancer syndrome: the impact of race on uptake of genetic counseling and testing. Methods Mol Biol 2009; 471: 487-500.20.20. Cass I, Baldwin RL, Varkey T et al. Improved survival in women with BRCA-associated ovarian carcinoma. Cancer 2003; 97 (9): 2187-95.21.21. Moslehi R, Chu W, Karlan B et al. BRCA1 and BRCA2 mutation analysis of 208 Ashkenazi Jewish women with ovarian cancer. Am J Hum Genet 2000; 66 (4): 1259-72.22.22. Struewing JP, Abeliovich D, Peretz T et al. The carrier frequency of the BRCA1 185delAG mutation is approximately 1% in Ashkenazi Jewish individuals. Nat Genet 1995; 11 (2): 198-200.23.23. Oddoux С, Struewing JP, Clayton CM et al. The carrier frequency of the BRCA2 6174delT mutation among Ashkenazi Jewish individuals is approximately 1%. Nat Genet 1996; 14 (2): 188-90.24.24. Roa BB, Boyd AA, Volcik K, Richards CS. Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2. Nat Genet 1996; 14 (2): 185-7.25.25. Boyd J. Specific keynote: hereditary ovarian cancer: what we know. Gynecol Oncol 2003; 88: 8-10.26.26. Смирнова Т.Ю., Поспехова Н.И., Любченко Л.Н. и др. Высокая частота мутаций в генах BRCA1 и BRCA2 при раке яичников. Бюл. эксперим. биол. и мед. 2007; 144 (7): 93-5.27.27. Brunet J, Perez-Segura P. Cancer screening and genetic counseling. Rev Оncol 2004; 6 (3): 176-83.28.28. Любченко Л.Н. Наследственный рак молочный железы и/или яичников: ДНК-диагностика, индивидуальный прогноз, лечение и профилактика. Автореф. дис. … канд. мед. наук, 2009.29.29. Смирнова Т.Ю., Любченко Л.Н., Поспехова Н.И. и др. Рак молочной железы и яичников. Роль наследственных факторов. Опухоли женской репродуктивной системы. 2007; 4: 90-6.30.30. Поспехова Н.И., Логинова A.H., Любченко Л.Н. и др. Молекулярно-генетические аспекты наследственной предрасположенности к раку молочной железы и/или яичников. С чем связана различная локализация рака при мутациях в гене BRCA1? Мед. генетика. 2005; 4 (1): 23-7.31.31. Поспехова Н.И., Логинова А.Н., Любченко Л.Н. и др. Гетерогенность семей с наследственной предрасположенностью к раку молочной железы по встречаемости мутаций в гене BRCA1. Мед. генетика. 2003; 2 (11): 459-63.32.32. Логинова А.Н., Поспехова Н.И., Любченко Л.Н. и др. Спектр мутаций в гене BRCAl при наследственных формах рака молочной железы и яичников в российских семьях. Бюл. эксперим. биол. мед. 2003; 136 (9): 315-7.33.33. Ford D, Easton DF, Stratton M et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet 1998; 62 (3): 676-89.34.34. Brose MS, Rebbeck TR, Calzone KA et al. Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program. J Natl Cancer Inst 2002; 94 (18): 1365-72.35.35. van der Velde NM, Mourits MJ, Arts HJ et al. Time to stop ovarian cancer screening in BRCA1/2 mutation carriers? Int J Cancer 2009; 124 (4): 919-23.36.36. Bakos AD, Hutson SP, Loud JT et al. BRCA mutation-negative women from hereditary breast and ovarian cancer families: a qualitative study of the BRCA-negative experience. Health Expect 2008; 11 (3): 220-31.37.37. Bermejo-Perez MJ, Marquez-Calderon S, Llanos-Mendez A. Cancer surveillance based on imaging techniques in carriers of BRCA1/2 gene mutations: a systematic review. Br J Radiol 2008; 81 (963): 172-9.38.38. Risch HA, McLaughlin JR, Cole DE et al. Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Am J Hum Genet 2001; 68 (3): 700-10.39.39. Antoniou A, Pharoah PD, Narod S et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 2003; 72 (5): 1117-30.40.40. Crotser CB, Boehmke M. Survivorship considerations in adults with hereditary breast and ovarian cancer syndrome: state of the science. J Cancer Surviv 2009; 3 (1): 21-42.41.41. Spurdle AB, Hopper JL, Chen X et al. The BRCA2 372 HH genotype is associated with risk of breast cancer in Australian women under age 60 years. Cancer Epidem Biomark Prev 2002; 11 (4): 413-6.42.42. Ginolhac SM, Gad S, Corbex M et al. BRCA1 wild-type allele modifies risk of ovarian cancer in carriers of BRCA1 germ-line mutations. Cancer Epidem Biomark Prev 2003; 12 (2): 90-5.43.43. Johnson N, Fletcher O, Palles C et al. Counting potentially functional variants in BRCA1, BRCA2 and ATM predicts breast cancer susceptibility. Hum Mol Genet 2007; 16 (9): 1051-7.44.44. Kurian AW, Balise RR, McGuire V et al. Histologic types of epithelial ovarian cancer: have they different risk factors? Gynecol Oncol 2005; 96 (2): 520-30.45.45. Chiaffarino F, Parazzini F, Bosetti C et al. Risk factors for ovarian cancer histotypes. Eur J Cancer 2007; 43 (7): 1208-13.46.46. Aida H, Takakuwa K, Nagata H et al. Clinical features of ovarian cancer in Japanese women with germ-line mutations of BRCA1. Clin Cancer Res 1998; 4 (1): 235-40.47.47. Rubin SC, Benjamin I, Behbakht K et al. Clinical and pathological features of ovarian cancer in women with germ-line mutations of BRCA1. N Engl J Med 1996; 335 (19): 1413-6.48.48. Johannsson ОТ, Ranstam J, Borg A et al. Survival of BRCA1 breast and ovarian cancer patients: a population-based study from southern Sweden. J Clin Oncol 1998; 16 (2): 397-404.49.49. Pharoah PD, Easton DF, Stockton DL et al. Survival in familial, BRCA1-associated, and BRCA2-associated epithelial ovarian cancer. Cancer Res 1999; 59 (4): 868-71.50.50. Чимитдоржиева Т.Н. Особенности клинического течения «семейного» рака яичников. Автореф. дис. … канд. мед. наук, 1998.51.51. Boyd J, Sonoda Y, Federici MG et al. Clinicopathologic features of BRCA-linked and sporadic ovarian cancer. JAMA 2000; 283 (17): 2260-5.52.52. David SP Tan, Rorhermundt C, Thomas K et al. Клинические особенности BRCA-синдрома при раке яичников: исследование типа «случай-контроль» у больных раком яичников с мутацией BRCA1 и BRCA2. J Clin Oncol (рус. изд.) 2008; 26 (34): 59-65.53.53. Ben David Y, Chetrit A, Hirsh-Yechezkel G et al. Effect of BRCA mutations on the length of survival in epithelial ovarian tumors. J Clin Oncol 2002; 20 (2): 463-6.54.54. Majdak EJ, Debniak J, Milczek T et al. Prognostic impact of BRCA1 pathogenic and BRCA1/BRCA2 unclassified variant mutations in patients with ovarian carcinoma. Cancer 2005; 104 (5): 1004-12.55.55. Chetrit A, Hirsh-Yechezkel G, Ben-David Y et al. Effect of BRCA1/2 mutations on long-term survival of patients with invasive ovarian cancer: the national Israeli study of ovarian cancer. J Clin Oncol 2008; 26 (1): 20-5.56.56. Brunet JS, Narod SA, Tonin P et al. BRCA1 mutations and survival in women with ovarian cancer. N Engl J Med 1997; 336 (17): 1256-7.57.57. Zweemer RP, Verheijen RH, Coebergh JW et al. Survival analysis in familial ovarian cancer, a case control study. Eur J Obstet Gynecol Reprod Biol 2001; 98 (2): 219-23.58.58. Buller RE, Shahin MS, Geisler JP et al. Failure of BRCA1 dysfunction to alter ovarian cancer survival. Clin Cancer Res 2002; 8 (5): 1196-202.59.59. Casey MJ, Bewtra C, Hoehne LL et al. Histology of prophylactically removed ovaries from BRCA1 and BRCA2 mutation carriers compared with noncarriers in hereditary breast ovarian cancer syndrome kindred's. Gynecol Oncol 2000; 78 (3 Pt. 1): 278-87.60.60. Рис М., Хоуп С., Охлер М.К. и др. Диагностика и лечение в гинекологии. Проблемный подход. Пер. с англ. Под ред. В.Н.Прилепской. М.: ГЭОТАР-Медиа, 2010.61.61. Pichert G, Bolliger В, Buser K et al. Evidence-based management options for women at increased breast/ovarian cancer risk. Ann Oncol 2003; 14 (1): 9-19.62.62. Bosse K, Rhiem K, Wappenschmidt B et al. Screening for ovarian cancer by transvaginal ultrasound and serum CA125 measurement in women with a familial predisposition: a prospective cohort study. Gynecol Oncol 2006; 103 (3): 1077-82.63.63. Lacey JV Jr, Greene MH, Buys SS et al. Ovarian cancer screening in women with a family history of breast or ovarian cancer. Obstet Gynecol 2006; 108 (5): 1176-84.64.64. Woodward ER, Sleightholme HV, Considine AM et al. Annual surveillance by CA125 and transvaginal ultrasound for ovarian cancer in both high-risk and population risk women is ineffective. BJOG 2007; 114 (12): 1500-9.65.65. McGuire V, Felberg A, Mills M et al. Relation of contraceptive and reproductive history to ovarian cancer risk in carriers and non carriers of BRCA1 gene mutations. Am J Epid 2004; 160 (7): 613-8.66.66. Godard В, Foulkes WD, Provencher D et al. Risk factors for familial and sporadic ovarian cancer among French Canadians: a case-control study. Am J Obstet Gynecol 1998; 179 (2): 403-10.67.67. Narod SA, Sun P, Risch HA. Ovarian cancer, oral contraceptives, and BRCA mutations. N Engl J Med 2001; 345 (23): 1706-7.68.68. Modan B, Hartge P, Hirsh-Yechezkel G et al. Parity, oral contraceptives, and the risk of ovarian cancer among carriers and noncarriers of a BRCA1 or BRCA2 mutation. N Engl J Med 2001; 345 (4): 235-40.69.69. Kauff ND, Satagopan JM, Robson ME et al. Risk-reducing salpingo-oophorectomy in women with BRCA1 or BRCA2 mutation. N Engl J Med 2002; 346 (21): 1609-15.70.70. Narod SA, Risch H, Moslehi R et al. Oral contraceptives and the risk of hereditary ovarian cancer. Hereditary Ovarian Cancer Clinical Study Group. N Engl J Med 1998; 339 (7): 424-8.71.71. Whittemore AS, Balise RR, Pharoah PD et al. Oral contraceptive use and ovarian cancer risk among carriers of BRCA1 or BRCA2 mutations. Br J Cancer 2004; 91 (11): 1911-5.72.72. Milne RL, Knight JA, John EM et al. Oral contraceptive use and risk of early-onset breast cancer in carriers and noncarriers of BRCA1 and BRCA2 mutations. Cancer Epid Biomark Prev 2005; 14 (2): 350-6.73.73. Rebbeck TR, Lynch НТ, Neuhausen SL et al. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 2002; 346 (21): 1616-22.74.74. Finch A, Beiner M, Lubinski J et al. Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 Mutation. JAMA 2006; 296 (2): 185-92.75.75. Domchek SM, Rebbeck TR. Prophylactic oophorectomy in women at increased cancer risk. Curr Opin Obstet Gynecol 2007; 19 (1): 27-30.76.76. Society of Gynecologic Oncologists Clinical Practice Committee Statement on Prophylactic Salpingo-oophorectomy. Gynecol Oncol 2005; 98 (2): 179-81.77.77. Armstrong K, Schwartz JS, Randall T et al. Hormone replacement therapy and life expectancy after prophylactic oophorectomy in women with BRCA1/2 mutations: a decision analysis. J Clin Oncol 2004; 22 (6): 1045-54.78.78. Julian-Reyniez C, Chabal F, Frebourg T et al. Professionals assess the acceptability of preimplantation genetic diagnosis and prenatal diagnosis for managing inherited predisposition to cancer. J Clin Oncol 2009; 27 (27): 4475-80.